The nucleoside analogue lamivudine (3TC) is commonly used in multidrug ther
apy of human immunodeficiency virus- 1 disease because it not only potentia
tes the antiviral effects of other reverse transcriptase inhibitors, but it
is also relatively nontoxic. We present a patient who developed a contact
dermatitis to lamivudine after prolonged exposure.